Financhill
Sell
47

VRTX Quote, Financials, Valuation and Earnings

Last price:
$480.47
Seasonality move :
4.76%
Day range:
$472.80 - $481.18
52-week range:
$377.85 - $519.88
Dividend yield:
0%
P/E ratio:
26.10x
P/S ratio:
11.10x
P/B ratio:
7.38x
Volume:
1.4M
Avg. volume:
1.6M
1-year change:
11.74%
Market cap:
$121.1B
Revenue:
$11B
EPS (TTM):
-$2.20

Analysts' Opinion

  • Consensus Rating
    Vertex Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 12 Hold ratings, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $497.87, Vertex Pharmaceuticals has an estimated upside of 5.54% from its current price of $471.76.
  • Price Target Downside
    According to analysts, the lowest downside price target is $330.00 representing 30.05% downside risk from its current price of $471.76.

Fair Value

  • According to the consensus of 29 analysts, Vertex Pharmaceuticals has 5.54% upside to fair value with a price target of $497.87 per share.

VRTX vs. S&P 500

  • Over the past 5 trading days, Vertex Pharmaceuticals has overperformed the S&P 500 by 3.14% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Vertex Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Vertex Pharmaceuticals has grown year-over-year revenues for 27 quarters straight. In the most recent quarter Vertex Pharmaceuticals reported revenues of $2.9B.

Earnings Growth

  • Vertex Pharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Vertex Pharmaceuticals reported earnings per share of $3.50.
Enterprise value:
115B
EV / Invested capital:
7.01x
Price / LTM sales:
11.10x
EV / EBIT:
412.14x
EV / Revenue:
10.44x
PEG ratio (5yr expected):
1.15x
EV / Free cash flow:
-117.61x
Price / Operating cash flow:
30.13x
Enterprise value / EBITDA:
236.54x
Gross Profit (TTM):
$9.5B
Return On Assets:
-2.4%
Net Income Margin (TTM):
-4.86%
Return On Equity:
-3.23%
Return On Invested Capital:
-3.23%
Operating Margin:
38.2%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $8.9B $9.9B $11B $2.5B $2.9B
Gross Profit $7.9B $8.6B $9.5B $2.1B $2.5B
Operating Income $4.4B $4.3B $4.4B $956M $1.1B
EBITDA $4.4B $4.6B $486.3M $1.2B $1.2B
Diluted EPS $12.83 $13.89 -$2.20 $3.71 $3.50
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $8.1B $9.6B $13.2B $14.1B $9.6B
Total Assets $11.8B $13.4B $18.2B $22.7B $22.5B
Current Liabilities $1.9B $2.1B $2.7B $3.5B $3.6B
Total Liabilities $3.1B $3.3B $4.2B $5.1B $6.1B
Total Equity $8.7B $10.1B $13.9B $17.6B $16.4B
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations $4.1B $3.5B -$492.6M $234.6M $584.6M
Cash From Investing -$321.1M -$3.1B -$3.8B -$886.5M -$821.9M
Cash From Financing -$67.7M -$562.2M -$1.5B -$119.8M -$391.3M
Free Cash Flow $3.9B $3.3B -$978M $118.5M $492M
VRTX
Sector
Market Cap
$121.1B
$44.2M
Price % of 52-Week High
90.74%
48.19%
Dividend Yield
0%
0%
Shareholder Yield
1.53%
-0.68%
1-Year Price Total Return
11.74%
-35.43%
Beta (5-Year)
0.413
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $462.90
200-day SMA
Buy
Level $462.81
Bollinger Bands (100)
Buy
Level 0 - 0
Chaikin Money Flow
Sell
Level --
20-day SMA
Buy
Level $457.95
Relative Strength Index (RSI14)
Buy
Level 64.08
ADX Line
Neutral
Level 0
Williams %R
Neutral
Level -35.2874
50-day SMA
Buy
Level $439.91
MACD (12, 26)
Buy
Level 8.48
25-day Aroon Oscillator
Buy
Level 60
On Balance Volume
Neutral
Level --

Financial Scores

Buy
Altman Z-Score (Annual)
Level (11.5862)
Buy
CA Score (Annual)
Level (0.9334)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-6.4552)
Sell
Piotroski F Score (Annual)
Level (3)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (7)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Stock Forecast FAQ

In the current month, VRTX has received 16 Buy ratings 12 Hold ratings, and 1 Sell ratings. The VRTX average analyst price target in the past 3 months is $497.87.

  • Where Will Vertex Pharmaceuticals Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Vertex Pharmaceuticals share price will rise to $497.87 per share over the next 12 months.

  • What Do Analysts Say About Vertex Pharmaceuticals?

    Analysts are divided on their view about Vertex Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vertex Pharmaceuticals is a Sell and believe this share price will drop from its current level to $330.00.

  • What Is Vertex Pharmaceuticals's Price Target?

    The price target for Vertex Pharmaceuticals over the next 1-year time period is forecast to be $497.87 according to 29 Wall Street analysts, 16 of them rate the stock a Buy, 1 rates the stock a Sell, and 12 analysts rate the stock a Hold.

  • Is VRTX A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Vertex Pharmaceuticals is a Buy. 16 of 29 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of VRTX?

    You can purchase shares of Vertex Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vertex Pharmaceuticals shares.

  • What Is The Vertex Pharmaceuticals Share Price Today?

    Vertex Pharmaceuticals was last trading at $480.47 per share. This represents the most recent stock quote for Vertex Pharmaceuticals. Yesterday, Vertex Pharmaceuticals closed at $471.76 per share.

  • How To Buy Vertex Pharmaceuticals Stock Online?

    In order to purchase Vertex Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Is SoFi Worth?
What Is SoFi Worth?

Since SoFi’s CEO began snapping up shares of the student…

Is CVX a Buy, Sell or Hold?
Is CVX a Buy, Sell or Hold?

Energy giant Chevron Corporation (NYSE:CVX) has long been a pure-play…

What Will NVIDIA Stock Be Worth in 2030?
What Will NVIDIA Stock Be Worth in 2030?

NVIDIA (NASDAQ:NVDA) has been by far one of the best…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 40x

Buy
60
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Sell
17
CE alert for Feb 21

Celanese [CE] is down 4.21% over the past day.

Sell
22
GLBE alert for Feb 20

Global E Online [GLBE] is down 8.41% over the past day.

Buy
72
HIMS alert for Feb 20

Hims & Hers Health [HIMS] is down 3.39% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock